Bsf Enterprise Plc · LSE:BSFA
Bsf Enterprise — Investor Presentation (July 2024)
22 slides from Bsf Enterprise's investor presentation, July 2024
Slide 1: Unlocking the next generation of biotech solutions
Unlocking the next generation of biotech solutions. LON: BSFA (UK) | BSFAF: QB (US) INVESTOR PRESENTATION July 2024 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 2: BSF develops advanced biotechnological solutions for sustainable materials and products
BSF develops advanced biotechnological solutions for sustainable materials and products across various sectors. Its core technology in industrial tissue engineering enables scalable production of lab-grown alternatives for consumer and medical markets, including lab-grown leather and cultivated meat
Slide 3: BSF Enterprise PLC - Board of Directors
BSF Enterprise PLC - Board of Directors Min Yang Geoffrey Baker Dr. Che Connon Dennis Ow Chair Director Managing Director Non-Executive Director § A wealth of experience § A qualified lawyer in § The first to 3D bio-print a § Formerly a business spanning over 30 years of in Australia and Hong Kong.
Slide 4: BSF Enterprise PLC - Management Team
BSF Enterprise PLC - Management Team Dr. Che Connon Geoffrey Baker Graham Duncan Ricardo Gouveia Managing Director Executive Director Marcelo Bravo CFO CSO CBO § The first to 3D bio-print a § A qualified lawyer in § A Chartered Accountant § Scientist with expertise in § Seasoned entrepreneur and hum
Slide 5: Biotech that addresses real challenges
Biotech that addresses real challenges. Livestock farming causes 24% of Protein Chicken Beef Pork greenhouse gas emissions, uses 33% of drinking water, and 66% of antibiotics. Impact on global warming -17% -52% -92% It leads to more deforestation than soy, palm oil, and wood combined. Cultured alter
Slide 6: A platform tissue engineering technology to create scaffold free structural tissues
A platform tissue engineering technology to create “scaffold free” structural tissues from cells SKIN[Leather] CORNEA MEAT | 06 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 7: What's Scaffold-Free?
What’s Scaffold-Free? § Tissues need structure and cells for proper texture, strength, and mouthfeel. § Lab-grown tissues often use synthetic or plant- based scaffolds for structure. § These scaffolds affect the natural feel and quality of the final product. § Our patented process lets cells create
Slide 8: Multiple Growth Opportunities
Multiple Growth Opportunities BSF Enterprise (Hong Kong) Ltd | 08 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 9: The UK's First Lab-Grown Steak
The UK’s First Lab-Grown Steak • On January 27, 2023, 3DBT produced the UK's first lab-grown fillet of 100% meat. • Using their patented City-Mix™, porcine cells were cultivated into pork fillets and strips with no plant-based scaffold. • This breakthrough means no animals were harmed, and the meat
Slide 10: City-Mix Media Additives
City-Mix™ Media Additives § Eliminates need for serum without hindering growth, cutting media costs by about 75%. § Patented, non-toxic, and food-safe formulations § Increases cell proliferation and production yield, reduces need for expensive growth factors, and facilitates tissue production. | 10
Slide 11: Kerato corneal technology
• Kerato aims to address the global shortage of donor human corneas for medical and research uses. CITY-MIX™ SALES • Developing an implantable medical device and an ocular toxicity testing platform. • Focused on transitioning 3DBT's corneal technology and IP into clinical trials. • Led by Dr. Sarah
Slide 12: Cultured Meat at Scale
Cultured Meat at Scale • 3DBT and CellulaRevolution Ltd have formed a JV to scale cultivated meat production. • CMT merges CellRev's bioprocessing expertise with 3DBT's City-Mix™ supplement. • This platform offers scalable, cost-competitive cultivated meat manufacturing. • Distribution through licen
Slide 13: BSF Enterprise (Hong Kong) Ltd
BSF Enterprise (Hong Kong) Ltd § Established presence in Hong Kong to access the Greater China market. § China consumes over 100 million tons of meat annually, a quarter of global consumption. § Developing a distribution network and partnering with biotech companies in cultivated meat, gene therapy,
Slide 14: Lab Grown Leather Ltd
Lab Grown Leather Ltd • In 2023, 3DBT bio-engineered samples of animal skin tissue. • BSF is initiating development programmes with major Global luxury goods companies • Now developing a separate business – Lab Grown Leather - to scale up technical development and operational sales of animal skin pr
Slide 15: 3DBT Skin: Real Leather Without The Animal
3DBT Skin : Real Leather Without The Animal | 15 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 16: The Global Leather Market
The Global Leather Market Market Shift Towards Sustainable Alternatives, growing faster than the overall market Significant potential to transform the leather goods market | 16 • GLOBAL RAW LEATHER INDUSTRY RESEARCH REPORT, COMPETITIVE LANDSCAPE, MARKET SIZE, REGIONAL STATUS AND PROSPECT • Raw Leath
Slide 17: Summary
Summary • BSF Enterprise PLC develops cutting-edge biotechnological solutions for sustainable materials, including lab-grown leather, cultivated meat and human corneas. • Differentiated superior tissue engineering platform to create “scaffold free” structural tissues, supporting multiple growth oppo
Slide 18: Appendix
Appendix ) LON:BSFA (UK) | BSFAF:QB (US) www.bsfenterprise.com © 2024 BSF Enterprise PLC. All rights reserved.
Slide 19: Investor Relations Information
Investor Relations Information. Shareholders % Holdings ADVISORS BSF Angel Funding LTD 16.13 Che Connon 12.55* Brokerage Shard Capital Brokers Newcastle University Holdings Ltd 6.72 Jarvis Inv Mgmt Ltd 6.58 UK Legal Hargreaves Lansdown plc 6.49 Reynolds Porter Chamberlain LLP Advance Plan Investment
Slide 20: Presentation Disclaimer
Presentation Disclaimer. The information contained in these slides and communicated orally to you, including the speech(es) of the presenter(s) and any materials distributed at or in connection therewith (together, the “Presentation”) is confidential. By reading the information contained in this Pre
Slide 21: Presentation Disclaimer (continued)
Presentation Disclaimer (continued). The Presentation has not been approved by the FCA and does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or
Slide 22: LON:BSFA (UK) | BSFAF:QB (US)
LON:BSFA (UK) | BSFAF:QB (US) www.bsfenterprise.com © 2024 BSF Enterprise PLC. All rights reserved.